The GALAHAD trial showed that people with metastatic castration-resistant prostate cancer (mCRPC) and inherited BRCA mutations had improved survival when treated with the PARP inhibitor, niraparib.
mCRPC does not respond to the hormone treatments that are common for metastatic prostate cancer. Instead, it grows despite treatment and causes death more often than other forms. Researchers are trying to develop more effective approaches to treat mCRPC.
One approach is based on a feature common in some mCRPC tumors. About one-fourth of mCRPC tumors have a mutation that disrupts repair of DNA damage. These include inherited mutations in the BRCA1, BRCA2, PALB2, BRIP1 genes among others. PARP inhibitors were developed to treat tumors like these with defective DNA repair.
The PARP inhibitor niraparib is approved to treat people with certain ovarian, fallopian tube or primary peritoneal cancers, with and without BRCA gene defects. Niraparib is not approved yet for treating prostate cancer.
The GALAHAD study looked whether niraparib improved outcomes for people with mCRPC. Participants with a mutation in BRCA1 or BRCA2 had better survival with niraparib treatment than people without a BRCA mutation. This benefited people with an inherited BRCA1 or BRCA2 mutation as well as those with a mutation only in their tumor. Most people had some side effects from niraparib, but these were similar to previous reports.
Bottomline: Niraparib is a promising treatment for mCRPC, particularly for people with BRCA1 or BRCA2 mutations.
Patient Advocate Faces Thyroid Cancer Decades After Surviving Breast Cancer
September 5th 2023‘I feel like I've gone to continuing education classes as an advocate through reentering the health system in the cancer space,’ FORCE executive director and founder Sue Friedman, a breast cancer survivor who recently received a diagnosis of thyroid cancer, tells CURE.
Read More
Stepping Up Again for Hereditary Cancer Prevention
February 25th 2023On Feb. 6, HB 2783 was introduced into the Arizona House. Hopefully this bill will help address some of the issues surrounding genetic testing, genetic counseling, and insurance coverage for those who might be at risk for hereditary cancer. My wife died of a cancer that was totally preventable. Nobody should die of a preventable cancer.
Read More